EpiScreen® - Enhanced immunogencity assessement solution
EpiScreen® – an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
Receive your quote directly from the manufacturer.
EpiScreen™ delivers all the required sensitivity, plus detailed data on specificity and mechanism of action, without the need for radioactive markers.
Identifying unwanted immunogenicity early on is critical to the success of your protein therapeutics. EpiScreen™ uses flow cytometry and not only delivers the levels of sensitivity you expect from older assays like [3H]-thymidine, but also allows you to characterize the responding immune cells by multiplexing the readout with cell activation markers. There’s also no need for radioactive reagents and the associated safety protocols. The result is an efficient process that gives you more confidence in your immunogenicity risk assessment.
To avoid issues later in the drug development process, you need to start smart. That means you need more data-rich assays at the start of your project. EpiScreen ™ allows you to assess immunogenicity via flow cytometry and completely avoid radioactive assays. You can also get a look at specific cell proliferation alongside customizable activation markers without ever compromising assay sensitivity.
EpiScreen ™ gives you better immunogenicity testing, which means better, more granular, candidate selection with fewer potential problems later down the line. Start smart, progress fast.
